Amneal Pharmaceuticals, INC

Amneal Pharmaceuticals announced that its stockholders have approved the acquisition of Kashiv BioSciences, LLC, with the transaction expected to close in the second half of 2026.

Amneal Pharmaceuticals announced strong second quarter 2026 results, exceeding expectations with a 10% revenue increase and raising full-year guidance, driven by growth in specialty and affordable medicines.

Amneal Pharmaceuticals announced first quarter 2026 results with net revenue of $723 million, a 4% increase year-over-year, and affirmed its full-year 2026 guidance.

Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for $375 million in cash and stock, plus potential milestone and royalty payments, aiming to bolster its global biosimilar capabilities and reported strong preliminary Q1 2026 results.

Amneal Pharmaceuticals announced strong fourth quarter and full year 2025 financial results, meeting or exceeding all guidance metrics and projecting continued growth for 2026.

Amneal Pharmaceuticals, Inc. has finalized a nationwide agreement to settle a substantial majority of opioid-related claims, involving $88.5 million in cash and up to $177.4 million in naloxone nasal spray.

Amneal Pharmaceuticals reports a significant increase in net income and gross profit for Q1 2026, driven by robust performance in its Specialty segment and improved manufacturing efficiencies.

Amneal Pharmaceuticals, Inc. reported a return to net income in Q3 2025, driven by revenue growth across all segments and strategic debt refinancing, despite an impairment charge and increased operating expenses.

Amneal Pharmaceuticals Inc. reported significant net income and EPS growth in Q2 2025, driven by new product launches and strategic segment performance, alongside major debt refinancing.

Amneal Pharmaceuticals' Q1 2025 revenue increased by 5.5% year-over-year, driven by growth in Affordable Medicines, AvKARE, and Specialty segments.

Amneal Pharmaceuticals saw a 13.3% increase in revenue year-over-year in Q3 2024, driven by growth in generics, specialty, and AvKARE segments.

Amneal Pharmaceuticals saw a 17.1% increase in revenue in Q2 2024, driven by growth in its Generics and AvKARE segments, while also navigating legal settlements and increased interest expenses.

Amneal Pharmaceuticals achieved significant revenue growth in 2025, driven by new product launches and biosimilar approvals, despite ongoing competitive and regulatory challenges.

Amneal Pharmaceuticals' 2024 10-K filing reveals a year of mixed financial performance, marked by strategic collaborations and a significant opioid litigation settlement.

Amneal Pharmaceuticals' 2023 10-K filing provides a comprehensive overview of its capital stock, business segments, financial performance, and risk factors, highlighting a year of strategic reorganization and operational expansion.

Amneal Pharmaceuticals Director Deborah M. Autor reported a sale of 34,819 shares of Class A Common Stock on May 11, 2026, for a weighted average price of $12.94 per share.

Director J. Kevin Buchi acquired 34,819 shares of Amneal Pharmaceuticals via restricted stock unit vesting and received a new grant of 19,824 units.

Director Deborah M. Autor acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Director Jeffrey P. George acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Director Gautam Patel acquired 34,819 shares of Amneal Pharmaceuticals via restricted stock unit vesting and was granted 19,824 new units.

Director John Kiely acquired 34,819 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Amneal Pharmaceuticals, Inc. reported robust financial and operational performance in 2025, driven by new product launches, double-digit revenue growth in key segments, and significant debt refinancing.

Amneal Pharmaceuticals has filed definitive additional proxy soliciting materials with the SEC.

Amneal Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on May 6, 2025, to vote on director elections, executive compensation, say-on-pay frequency, and auditor ratification.

Amneal Pharmaceuticals has filed a definitive proxy statement with the SEC.

Amneal Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on May 2, 2024, to vote on director elections, executive compensation, and the ratification of its independent auditor.

Dipan Patel's trusts sold nearly 7 million shares of Amneal Pharmaceuticals Class A Common Stock, reducing beneficial ownership to 5.4%.

Chintu Patel, a significant shareholder of Amneal Pharmaceuticals, Inc., has pledged over 13.2 million Class A Common Stock shares as collateral for a margin loan agreement with Citibank, N.A.

A trust controlled by Amneal Pharmaceuticals' significant shareholder, Dipan Patel, has pledged 3,050,000 Class A Common Stock shares as collateral for a $10 million loan from Enterprise Bank & Trust.

Chirag Patel and related trusts increased pledged Amneal Pharmaceuticals Class A Common Stock to 19 million shares and extended the maturity of a margin loan agreement with UBS to April 29, 2028.

Tushar Patel, a significant beneficial owner of Amneal Pharmaceuticals, Inc., sold 5 million shares of Class A Common Stock for $8.35 per share to obtain liquidity.

Dipan Patel, through controlled trusts, sold over 3 million shares of Amneal Pharmaceuticals stock between July and November 2024, reducing his beneficial ownership to 7.7%.

The Vanguard Group reported 0% beneficial ownership of Amneal Pharmaceuticals Inc. following an internal realignment, with subsidiaries now reporting separately.

Akram Mahesh has reported a beneficial ownership of 6.56% of Amneal Pharmaceuticals, Inc.'s Class A Common Stock as of March 31, 2025, through trusts managed by his wholly-owned Tattva Fiduciary Company.

The Vanguard Group has filed a Schedule 13G, reporting a 5.02% beneficial ownership stake in Amneal Pharmaceuticals Inc., totaling 15,762,727 shares of common stock.

UBS Group AG has filed an amended Schedule 13G for Amneal Pharmaceuticals, Inc., reporting zero beneficial ownership of Class A Common Stock as of December 31, 2024, following its acquisition of Credit Suisse Group AG.